Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 2, 2001, Pages 142-148

  De Mey, Christian ^a,b,c,d   Althaus, Michael ^a,b,c,d   Ezan, Eric ^a,b,c,d   Retzow, Angelika ^a,b,c,d,e  

^a Appl Clinical Pharmacology Services   (Germany)

^b ALK SCHERAX Arzneimittel GmbH   (Germany)

^c Institut National de la Recherche Agronomique   (France)

^d Reinfeld ^*  (Germany)

^e ACPS Applied Clinical Pharmacology Services   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOCRYPTINE; DRUG METABOLITE; ERYHEXAL; ERYTHROMYCIN;

ABDOMINAL PAIN; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; MUSCLE WEAKNESS; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROERGOTOXINE; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; ERYTHROMYCIN; HUMANS; MALE; MIXED FUNCTION OXYGENASES; RADIOIMMUNOASSAY;

EID: 0034894070     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.117286     Document Type: Article

References (21)

1. Dopamine receptor profile of co-dergocrine (Hydergine®) and its components
2. Alpha-dihydroergocryptine in Parkinson's disease: A multicentre randomized double blind parallel group study
3. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomized, double-blind, placebo-controlled study
4. Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction
5. In vitro identification of the cytochrome P450 isoenzyme responsible for the metabolism of α-dihydroergocryptine
6. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
7. High affinity of ergopeptides for cytochrome P450 3A
8. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
9. Ergotism in a psychiatric setting caused by combined dihydroergotamine-erythromycin propionate. Apropos of a case
10. Psicosis por interacción de eritromicina con bromocriptina en enfermedad de Parkinson
11. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
12. Pharmcokinetic drug interactions of macrolides
13. Macrolide antibacterials. Drug interactions of clinical significance
14. Highly sensitive and specific radioimmunoassays for dihydroergotoxine components in plasma
15. Bioequivalence study of α-dihydroergocryptine: Utility of metabolite evaluation
16. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
17. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
18. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talindol in humans
19. Bromocriptine modulates P-glycoprotein function